Synthesis, in vitro and in silico assessment of organometallic Rhenium(I) and Technetium(I) thymidine complexes

Thymidine kinases have been identified as suitable targets for non-invasive imaging of gene therapy and cancer. Thus, there is a high interest in new, reliable and inexpensive radiolabeled thymidine analogues for these applications. In this study we present the synthesis and in vitro evaluation of M(CO)3-complexes of thymidine (M = 99mTc, Re) for potential use in SPECT tumor imaging. 5′-amino-5′-deoxythymidine was derivatized at position C5′ with spacers of various lengths (∼0–30 Å) carrying tridentate metal chelating entities such as iminodiacetic acid and picolylamine-N-monoacetic acid. The nucleoside derivatives were reacted with the precursors [ReBr3(CO)3]2− and [99mTc(OH2)3(CO)3]+, respectively. The organometallic thymidine complexes have been fully characterized by means of IR, NMR and mass spectrometry. Enzyme kinetic studies revealed mixed inhibition of the human cytosolic thymidine kinase with Ki values ranging from 4.4 to 334 μM for all thymidine complexes. Competitive inhibition of herpes simplex virus type 1 thymidine kinase was only achieved when thymidine and the metal core were separated by a spacer of approximately 30 Å length. These findings were supported by in silico molecular docking and molecular dynamic experiments.

Organometallic technetium and rhenium complexes of 5′-amino-5′-deoxythymidine derivatives were synthesized. Enzyme kinetic studies revealed mixed (uncompetitive) inhibition of human TK for all complexes. The complex with a spatial separation of the thymidine and the metal entities by ∼30 Å revealed competitive inhibition of HSV1 TK. Molecular dynamic calculations confirmed these experimental findings.Figure optionsDownload as PowerPoint slide